So far, extensive studies have confirmed that BCC development is orchestrated by mutations in the Sonic Hedgehog pathway regulators, especially in the Patched 1 receptor (PTCH1) and G-protein-coupled receptor Smoothened (SMO) which eventually results in the activation of nuclear, GLI-dependent growth programs [24]. The gene discussed is SMO; the disease is skin basal cell carcinoma.